ESR1 and breast carcinoma: A phase I study sponsored by Washington University School of Medicine in collaboration with NCI aimed to determine the toxicity profile and the MTD of Buparlisib with Fulvestrant in estrogen receptor (ER)+ stage IV breast cancer patients [138].